Ownership
Private
Therapeutic Areas
PsychiatryNeurology
Stage
Phase 2
Modalities
Small molecule

Recognify Life Sciences General Information

Lead compound RL-007 has been evaluated in 9 clinical studies (7 Phase I, 2 Phase II) with 508 subjects. Three trials showed improvements in verbal learning and memory. The compound demonstrated pro-cognitive effects in preclinical studies and showed anxiolytic properties in animal models.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
New York, New York
United States

Drug Pipeline

RL-007
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Recognify Life Sciences's pipeline data

Book a demo

Key Partnerships

atai Life Sciences

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Recognify Life Sciences Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Recognify Life Sciences's complete valuation and funding history, request access »

Recognify Life Sciences Investors

ATAI Life Sciences (majority stakeholder)
Investor Type: Venture Capital
Holding: Minority